+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Paroxysmal Nocturnal Hemoglobinuria Treatment Market - Global Forecast 2026-2032- Product Image
Paroxysmal Nocturnal Hemoglobinuria Treatment Market - Global Forecast 2026-2032- Product Image
New

Paroxysmal Nocturnal Hemoglobinuria Treatment Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 196 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968573
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Paroxysmal Nocturnal Hemoglobinuria (PNH) treatment market is undergoing a profound transformation, shaped by growing clinical complexity, evolving commercial models, and increasing pressure for optimized patient outcomes. Senior leaders must interpret shifting market forces to maintain operational agility and unlock sustainable value in this rare disease therapeutic sector.

Market Snapshot: Paroxysmal Nocturnal Hemoglobinuria Treatment Market

The Paroxysmal Nocturnal Hemoglobinuria treatment market expanded from USD 5.84 billion in 2025 to USD 6.25 billion in 2026, with expectations to reach USD 9.55 billion by 2032 at a CAGR of 7.27%. This sustained growth underscores robust demand for advanced therapies tailored to gaps in hematology and rare disease management. Market momentum results from ongoing innovation, adaptive reimbursement mechanisms, and a fundamental shift toward care models placing patients at the center of therapeutic strategies.

Scope & Segmentation

  • Treatment Classes: Complement inhibitors, gene therapies, and supportive interventions each contribute uniquely to optimizing PNH treatment paradigms and expanding therapeutic options for various patient needs.
  • Administration Frequencies: Long-acting, standard, and frequent dosing schedules provide adaptable solutions accommodating provider capabilities and patient preferences, enhancing adherence and outcomes.
  • Distribution Channels: Hospital pharmacies, online specialty platforms, and retail locations shape the environment for drug dispensing, patient support, and logistical coordination.
  • Patient Care Settings: Home care, hospitals, and specialty clinics affect resource allocation, monitoring capabilities, and the overall care experience.
  • Route of Administration: Intravenous and subcutaneous methods require customized site support and tailored training for effective implementation and patient comfort.
  • Line of Therapy: First-line, second-line, and third-line strategies inform treatment sequencing, commercial positioning, and coverage decision-making.
  • Dosage Strengths: Categories spanning high, low, and standard dosing introduce variability in therapeutic monitoring and real-world clinical management.
  • Regions Covered: Americas, Europe, Middle East & Africa, and Asia-Pacific, each bringing distinct regulatory landscapes, commercial frameworks, and access considerations to stakeholder strategy.

Key Takeaways for Senior Decision-Makers

  • Rapid advances in PNH management are centering care around targeted complement inhibition and gene-based approaches, emphasizing precision and customization in treatment planning.
  • Care models are shifting, with new administration and dosing innovations reducing dependence on infusion centers and broadening patient reach to underserved geographies.
  • Strategic collaborations across the industry and the adoption of value-based reimbursement models are expediting late-stage pipeline development and enabling broader patient access initiatives.
  • Segmented strategies based on therapy type, distribution, and care setting are necessary to identify portfolio white spaces and deliver agile, subsegment-focused commercialization.
  • Regional diversity in policies, payer systems, and infrastructure necessitates locally informed evidence generation and tailored pricing or entry strategies for optimal resource allocation.
  • Organizations aligning clinical and commercial investments to reflect these varied influences position themselves for sustained operational strength and competitive resilience.

Tariff Impact: Navigating U.S. Tariff Adjustments in PNH Therapy Supply Chains

Recent tariff adjustments in the United States are introducing cost pressures and additional complexity for manufacturers, distributors, and healthcare providers managing PNH therapy supply chains. To preserve product availability and control rising input expenses, teams must intensify procurement agility and reinforce supply chain continuity. Approaches such as vertical integration, expanding local sourcing, and developing alternative supplier networks can help mitigate supply interruptions and safeguard margins. Proactively engaging payers and decision-makers through transparent communication and robust risk modeling will support continued patient access. Policy considerations, including selective tariff exemptions, have the potential to relieve constraints on essential medicines and ensure therapy availability remains stable.

Methodology & Data Sources

This analysis follows a rigorous mixed-method approach, integrating primary expert interviews with clinicians, pharmacy leaders, and commercial executives. Secondary research sources include peer-reviewed studies, regulatory filings, and public datasets. All findings undergo triangulation and are validated through scenario modeling and segmentation analyses to ensure decision-ready insights.

Why This Report Matters

  • Empowers senior stakeholders to benchmark strategic priorities against nuanced, region-specific, and segment-driven trends across the global PNH treatment market.
  • Delivers evidence-backed insight to guide investment and operational choices for established and emerging market participants navigating regulatory and commercial complexities.
  • Equips decision-makers with structured frameworks for expanding access, driving therapeutic innovation, and mitigating evolving risks in the PNH domain.

Conclusion

The PNH treatment market is navigating multifaceted clinical, regulatory, and operational change as it evolves toward more patient-focused and value-based care standards. Organizations that incorporate granular insights and adaptive strategies will be best positioned to deliver reliable value and sustained impact in this dynamic landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Treatment Class
8.1. Complement Inhibitors
8.1.1. Eculizumab
8.1.2. Ravulizumab
8.2. Gene Therapies
8.3. Supportive Therapies
8.3.1. Blood Transfusion
8.3.2. Iron Chelation Therapy
9. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Administration Frequency
9.1. Every Eight Weeks
9.2. Every Two Weeks
10. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Route of Administration
10.1. Intravenous Administration
10.2. Subcutaneous Administration
11. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Line of Therapy
11.1. First Line
11.2. Second Line
11.3. Third Line
12. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Dosage Strength
12.1. High Dose
12.2. Low Dose
12.3. Standard Dose
13. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by End User
13.1. Home Care Settings
13.2. Hospitals
13.3. Specialty Clinics
14. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Distribution Channel
14.1. Hospital Pharmacy
14.2. Online Pharmacy
14.3. Retail Pharmacy
15. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Region
15.1. Americas
15.1.1. North America
15.1.2. Latin America
15.2. Europe, Middle East & Africa
15.2.1. Europe
15.2.2. Middle East
15.2.3. Africa
15.3. Asia-Pacific
16. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Group
16.1. ASEAN
16.2. GCC
16.3. European Union
16.4. BRICS
16.5. G7
16.6. NATO
17. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Country
17.1. United States
17.2. Canada
17.3. Mexico
17.4. Brazil
17.5. United Kingdom
17.6. Germany
17.7. France
17.8. Russia
17.9. Italy
17.10. Spain
17.11. China
17.12. India
17.13. Japan
17.14. Australia
17.15. South Korea
18. United States Paroxysmal Nocturnal Hemoglobinuria Treatment Market
19. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market
20. Competitive Landscape
20.1. Market Concentration Analysis, 2025
20.1.1. Concentration Ratio (CR)
20.1.2. Herfindahl Hirschman Index (HHI)
20.2. Recent Developments & Impact Analysis, 2025
20.3. Product Portfolio Analysis, 2025
20.4. Benchmarking Analysis, 2025
20.5. Akari Therapeutics Plc
20.6. Alnylam Pharmaceuticals, Inc.
20.7. Amgen Inc.
20.8. Apellis Pharmaceuticals, Inc.
20.9. AstraZeneca plc
20.10. F. Hoffmann-La Roche Ltd.
20.11. Genentech, Inc.
20.12. Novartis AG
20.13. Regeneron Pharmaceuticals, Inc.
20.14. Samsung Bioepis Co., Ltd.
20.15. Swedish Orphan Biovitrum AB
List of Figures
FIGURE 1. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 15. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ECULIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ECULIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY IRON CHELATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY IRON CHELATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY IRON CHELATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY EIGHT WEEKS, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY EIGHT WEEKS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY EIGHT WEEKS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY TWO WEEKS, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY TWO WEEKS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY TWO WEEKS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HIGH DOSE, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HIGH DOSE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HIGH DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LOW DOSE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LOW DOSE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LOW DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STANDARD DOSE, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STANDARD DOSE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STANDARD DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 83. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
TABLE 85. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
TABLE 86. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 87. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 88. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 89. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 90. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 103. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
TABLE 105. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
TABLE 106. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 121. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 123. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 124. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
TABLE 125. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
TABLE 126. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 127. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 128. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 129. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 133. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 139. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 140. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 141. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 143. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 144. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
TABLE 145. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
TABLE 146. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 147. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 148. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 149. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 150. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 161. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 162. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 164. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 165. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
TABLE 166. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
TABLE 167. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 168. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 169. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 170. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 171. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 172. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 173. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 174. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 175. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
TABLE 176. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
TABLE 177. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 178. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 179. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 180. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 181. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 192. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 194. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 195. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
TABLE 196. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
TABLE 197. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 198. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 199. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 200. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 201. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 202. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 203. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 204. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 205. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
TABLE 206. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
TABLE 207. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 208. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 209. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 210. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 211. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 212. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 213. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 214. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 215. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
TABLE 216. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
TABLE 217. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 218. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 219. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 220. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 221. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 222. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 223. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 224. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 225. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 226. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
TABLE 227. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
TABLE 228. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 229. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 230. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 231. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 232. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 233. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 234. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 235. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 236. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2032 (USD MILLION)
TABLE 237. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2032 (USD MILLION)
TABLE 238. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 239. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 240. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
TABLE 241. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 242. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Paroxysmal Nocturnal Hemoglobinuria Treatment market report include:
  • Akari Therapeutics Plc
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • AstraZeneca plc
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Samsung Bioepis Co., Ltd.
  • Swedish Orphan Biovitrum AB

Table Information

Report AttributeDetails
No. of Pages196
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 6.25 Billion
Forecasted Market Value ( USD ) by 2032 $ 9.55 Billion
Compound Annual Growth Rate7.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment - Global Strategic Business Report - Product Image

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment - Global Strategic Business Report

  • Report
  • 126 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria Drugs Market - Global Forecast 2025-2030 - Product Image

Paroxysmal Nocturnal Hemoglobinuria Drugs Market - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria (Pnh) Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Paroxysmal Nocturnal Hemoglobinuria (Pnh) Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Report 2025 - Product Image

Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Paroxysmal Nocturnal Haemoglobinuria - Pipeline Insight, 2025 - Product Image

Paroxysmal Nocturnal Haemoglobinuria - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From

About the Paroxysmal Nocturnal Hemoglobinuria Drug Market

The Paroxysmal Nocturnal Hemoglobinuria (PNH) drug market is a specialized segment within the broader category of hematological drugs, which encompasses medications for a wide range of blood disorders. PNH is a rare, life-threatening blood disease characterized by the destruction of red blood cells, leading to hemoglobin release in the urine, particularly noticeable at night or in the early morning. Treatments for PNH focus on reducing hemolysis, preventing thrombosis, and improving quality of life. Historically, the management of PNH involved supportive treatments such as blood transfusions and iron therapy; however, the advent of novel targeted therapies has transformed the therapeutic landscape. These innovative drugs inhibit the complement system, which plays a central role in the pathophysiology of PNH. The development and approval of these complement inhibitors have provided patients with the first disease-specific treatments, substantially improving clinical outcomes. Several companies have made their mark in the PNH drug market, with a strong focus on research and development for more effective and patient-friendly treatments. Leading players include Alexion Pharmaceuticals, Inc., which developed eculizumab, a monoclonal antibody that has been a cornerstone in PNH treatment. Other notable companies operating in the space are Apellis Pharmaceuticals, which has made strides with its complement inhibitor pegcetacoplan, and Novartis, exploring gene-therapy approaches to provide long-term relief for patients afflicted by the disorder. These companies, along with others engaged in the Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.